TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04919343

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BBC Education Tiny Happy People videos
Description: This intervention involves regular texting of BBC Education Tiny Happy People videos to parents

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical health control intervention
Description: This intervention involves regular texting of publicly available videos about supporting infant physical and dental health to parents
Study: NCT05687565

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control group placebo
Description: Dietary suplementation

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Experimental group 1 lauric acid
Description: Lauric acid 1.5 grams once daily

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Experimental group 2 lauric acid
Description: Lauric acid 3 grams once daily
Study: NCT04617223

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Endoscopic sinus evacuation
Description: Evacuation of the sinus by using endoscope
Study: NCT04724200

Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiogram
Description: Echocardiography plays a crucial role in the diagnosis of HF; it is the standard of care imaging modality used to confirm the diagnosis, it permits real-time imaging of the heart and quantitative assessment of cardiac structure and function, crucial for diagnosis.
Study: NCT06129682

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self rehabilitation at home
Description: 6 week program of exercise at home of gradual intensity and duration
Study: NCT06197516

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Integrated Neuromuscular Inhibition Technique
Description: After palpating the trigger point ischemic compression were applied for 20-60 sec while strain Counterstain for 60-90 sec and MET is for 7-10 sec.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neuromuscular Reeducation Technique
Description: Deep pressure were applied along origin and insertion of Piriformis and hamstring muscle combined with active movement of patient for 5 -15 time as per required
Study: NCT03547232

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indomethacin SR
Description: Indomethacin SR 50mg given q12h from admission day 1 to day 7

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Placebos
Description: Similar shape and size suppositories (Placebos) without indomethacin given q12h from admission day 1 to day 7
Study: NCT06131593

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAPB with dexamethasone as an adjuvant to local anesthetics
Description: patients will receive TAPB with dexamethasone as an adjuvant to bupivacaine and lidocaine local anesthetics

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TAPB with methylprednisolone as an adjuvant to local anesthetics
Description: patients will receive TAPB with methylprednisolone as an adjuvant to bupivacaine and lidocaine local anesthetics
Study: NCT05678673

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XL092
Description: Specified doses on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified doses on specified days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sunitinib Malate
Description: Specified doses on specified days
Study: NCT05881083

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 1-week nicotine replacement therapy sampling
Description: Participants will be given an 1-week sample of nicotine replacement therapy (patch or gum) with brief instructions on how to use the product

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief cessation advice
Description: Participants will receive brief cessation advice following the AWARD (ask, warn, advise, refer, do-it-again) model:~A: Ask about the tobacco use status; W: Warn about the hazards of tobacco use; A: Advise the smokers to quit; R: Refer the smokers to cessation services; D: Do-it-again

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief cessation advice
Description: Participants will receive brief cessation advice following the AWARD (ask, warn, advise, refer, do-it-again) model:~A: Ask about the tobacco use status; W: Warn about the hazards of tobacco use; A: Advise the smokers to quit; R: Refer the smokers to cessation services; D: Do-it-again
Study: NCT06340594

Intervention type: PROCEDURE
Intervention: Laproscopic cholecystectomy (LC)
Description: Removal of gallbladder via laparoscopy

Intervention type: PROCEDURE
Intervention: Laproscopic cholecystectomy (LC)
Description: Removal of gallbladder via laparoscopy

Intervention type: PROCEDURE
Intervention: Endoscopic Retrograde Cholangiopancreatography (ERCP)
Description: Removal of bile duct stones via endoscopy

Intervention type: PROCEDURE
Intervention: Endoscopic Retrograde Cholangiopancreatography (ERCP)
Description: Removal of bile duct stones via endoscopy
Study: NCT06449261

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spinal Manual therapy used in Physiotherapy Practice
Description: C5-C6 and thoracic spine mobilization with postural correction

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Spinal Manual therapy used in Physiotherapy Practice
Description: C5-C6 and thoracic spine mobilization with postural correction
Study: NCT06738485

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant single-chain factor VIII (rVIII-SingleChain)
Description: Lyophilized powder for solution for intravenous injection
Study: NCT06734494

Intervention type: DEVICE
Intervention: Laparoscopic appendectomy Laparoscopic appendectomy with Airseal or with standard insufflation
Description: Airseal is a constant and low-pressure insufflation device. Standard insufflation is a variable pressure insufflation device.

Intervention type: DEVICE
Intervention: Laparoscopic appendectomy Laparoscopic appendectomy with Airseal or with standard insufflation
Description: Airseal is a constant and low-pressure insufflation device. Standard insufflation is a variable pressure insufflation device.
Study: NCT06725277

Intervention type: DRUG
Intervention: Spravato
Description: Intranasal esketamine

Intervention type: DRUG
Intervention: IV Ketamine
Description: IV ketamine
Study: NCT06741163

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pre-activity shot
Description: Water-based shot containing olive leaf extract (100mg Oleuropein), vitamins, and other active ingredients. The product will be provided in sterilized Nalgene bottles of 60 mL, equivalent to one dose. Participants will consume one dose of the test product before their training session on each intervention day (Day 5, Day 6, and Day 7).

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Water-based shot with similar appearance and taste but without the active ingredients of the test product. The placebo will be provided in sterilized Nalgene bottles of 60 mL, equivalent to one dose. Participants will consume one dose of the placebo before their training session on each intervention day (Day 5, Day 6, and Day 7).
Study: NCT06734403

Intervention type: OTHER
Intervention: Bladder Augmentation
Description: Bladder Augmentation using bowel loop (ileal or sigmoid loop)

Intervention type: OTHER
Intervention: Bladder Augmentation
Description: Bladder Augmentation using bowel loop (ileal or sigmoid loop)
Study: NCT06743126

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMA203
Description: one-time administration of IMA203, and adjunctive therapy with low dose interleukin (IL)-2 for up to 10 days, starting approximately 24 h after IMA203 infusion, optional bridging therapy

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: nivolumab plus relatlimab
Description: in accordance with current respective prescribing information (PI) and/or summary of product characteristics (SmPC)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: lifileucel
Description: in accordance with current respective prescribing information (PI) and/or summary of product characteristics (SmPC)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: nivolumab
Description: in accordance with current respective prescribing information (PI) and/or summary of product characteristics (SmPC)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: pembrolizumab
Description: in accordance with current respective prescribing information (PI) and/or summary of product characteristics (SmPC)
Study: NCT05077449

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + Fulvestrant
Description: Placebo 360 mg orally Twice daily(Q12H) of every 28-day cycle Fulvestrant 500mg intramuscular injection on day 1 and day 15 for the first cycle and then on day 1 for every cycle (28-day) until progressive disease
Study: NCT04405479

Intervention type: BEHAVIORAL
Intervention: Examination of tremor and upper hand functions
Description: Participants will be only examined. They will not undergo any intervention.

Intervention type: BEHAVIORAL
Intervention: Examination of tremor and upper hand functions
Description: Participants will be only examined. They will not undergo any intervention.
Study: NCT05997108

Intervention type: DIAGNOSTIC_TEST
Intervention: CBC
Description: Platelet and red blood cell volume indices

Intervention type: DIAGNOSTIC_TEST
Intervention: CBC
Description: Platelet and red blood cell volume indices
Study: NCT05846282

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STRIVE
Description: The STRIVE intervention will include all activities and BREATHE skill training components of L2B with content framed within the needs of high achieving college-bound BIPOC students who can benefit from health promoting practices to offset the costs of resilience. The intervention will include twelve 60-minute group sessions, with two sessions on each of the six core themes. Each session will include an opening mindful movement, short didactic presentation of the topic or theme of that week, group activities that illustrate the theme, guided discussion about the activity, and in-session group mindfulness meditation practice.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Study Skills
Description: The sessions will focus on goal setting (4 sessions), organization and time management (3 sessions), and study skills for reading comprehension, writing papers, note-taking, and test-taking (4 sessions). Parallel to the final L2B session, the last meeting will include activities to share and reflect on how students plan to incorporate and sustain new skills.
Study: NCT05862545

Intervention type: DRUG
Intervention: BGF (budesonide/glycopyrrolate/formoterol fumarate)
Description: BGF is a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an ICS and a LABA, or a combination of a LABA and a LAMA. The decision to start treatment with BGF must be made by the treating physician according to the subjects' medical need and a positive benefit/risk balance. The decision to prescribe BGF must be independent of enrolment into the study, must be determined by the treating physician and should be taken according to the standard of current best medical practice and national guidelines.
Study: NCT05703360

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Audiovisual Stimulation
Description: The device application involves the 3D multiple-object-tracking (3D-MOT) paradigm composed of 8 high-contrast spheres which are adapted to the visual ability of participant (luminosity and size). The initial speed of the spheres is adjustable and determined during the inclusion visit.~One or more of the spheres is temporarily highlighted (target). Then all 8 spheres move for 20 seconds following random linear paths, bouncing on one another and on the walls of a virtual 3D cube when collisions occur. After 20 seconds, the movement stops and the participant is asked to select, using the hand controller, the initially highlighted target(s) among the 8 spheres. If the selection is correct the speed of the spheres in the next trial is increased. If the selection is incorrect the speed of the spheres in the next trial is decreased.~Based on performance, stimulations will be adjusted to change difficulty level (e.g. changing backgrounds, number of cued balls, etc.)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Audiovisual Stimulation
Description: The device application involves the 3D multiple-object-tracking (3D-MOT) paradigm composed of 8 high-contrast spheres which are adapted to the visual ability of participant (luminosity and size). The initial speed of the spheres is adjustable and determined during the inclusion visit.~One or more of the spheres is temporarily highlighted (target). Then all 8 spheres move for 20 seconds following random linear paths, bouncing on one another and on the walls of a virtual 3D cube when collisions occur. After 20 seconds, the movement stops and the participant is asked to select, using the hand controller, the initially highlighted target(s) among the 8 spheres. If the selection is correct the speed of the spheres in the next trial is increased. If the selection is incorrect the speed of the spheres in the next trial is decreased.~Based on performance, stimulations will be adjusted to change difficulty level (e.g. changing backgrounds, number of cued balls, etc.)
Study: NCT05337540

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EVI-01
Description: Single intra-articular injection of high molecular weight hyaluronic acid

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EVI-01
Description: Single intra-articular injection of high molecular weight hyaluronic acid

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active comparator Synvisc-One
Description: Single intra-articular injection of active comparator Synvisc-One
Study: NCT05464186

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Whole milk
Description: Weekly home delivery of whole milk, daily text messages, monthly virtual visits

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nonfat milk
Description: Weekly home delivery of nonfat milk, daily text messages, monthly virtual visits
Study: NCT06377410

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Syrup Prospan
Description: Participant with stable COPD who received Syrup prospan for 1 month

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N-Acetylcysteine
Description: Participant with stable COPD who received N-Acetylcysteine for 1 month
Study: NCT05761652

Intervention type: OTHER
Intervention: Observe and record
Description: The general information, environmental indicators, and auxiliary examination indicators of the subjects were observed and recorded, as well as the TCM physical assessment was performed.

Intervention type: OTHER
Intervention: Observe and record
Description: The general information, environmental indicators, and auxiliary examination indicators of the subjects were observed and recorded, as well as the TCM physical assessment was performed.
Study: NCT05244720

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Fibroscan
Description: A percutaneous scan, that measures shear wave velocity. It estimates liver stiffness.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Fibroscan
Description: A percutaneous scan, that measures shear wave velocity. It estimates liver stiffness.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Blood samples
Description: Blood samples to asses the function of liver, kidney and bone marrow, as well as nutrition/vitamin status.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood samples
Description: Blood samples to asses the function of liver, kidney and bone marrow, as well as nutrition/vitamin status.
Study: NCT06179173

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIIT-RCE
Description: High-intensity interval training on semi-recumbent cycle ergometer

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional physiotherapy
Description: Conventional physiotherapy
Study: NCT03703258

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: App-based intervention
Description: A app-based cognitive-behavioral intervention to prevent the development of PTSD and high-risk drinking in recently-victimized adults
Study: NCT06743126

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ipilimumab
Description: in accordance with current respective prescribing information (PI) and/or summary of product characteristics (SmPC)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dacarbazine
Description: in accordance with current respective prescribing information (PI) and/or summary of product characteristics (SmPC)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: temozolomide
Description: in accordance with current respective prescribing information (PI) and/or summary of product characteristics (SmPC)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel
Description: in accordance with current respective prescribing information (PI) and/or summary of product characteristics (SmPC)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel plus carboplatin
Description: in accordance with current respective prescribing information (PI) and/or summary of product characteristics (SmPC)
Study: NCT05267028

Intervention type: OTHER
Intervention: AD-TAR
Description: 12 sessions in groups of 4 subject, over 6 weeks (2 sessions per week), using a rehabilitation program named Training of Affect Recognition (TAR).

Intervention type: OTHER
Intervention: AD-Cognitive Stimulation
Description: 12 sessions in groups of 4 subject, over 6 weeks (2 sessions per week), using classic cognitive stimulation workshops.
Study: NCT05873530

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Grape
Description: Reconstituted whole grape powder
Study: NCT05015751

Intervention type: DEVICE
Intervention: Thermal Anisotropy Measurement Device
Description: A wireless device for non-invasively assessing CSF shunt flow.
Study: NCT05445180

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency management
Description: Contingency management will be used to encourage abstinence

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency management
Description: Contingency management will be used to encourage abstinence
Study: NCT05937451

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PRIME solution
Description: The investigators will apply an AKI prediction model (PRIME solution) based on the patient's demographic. The investigators will collect data on vital signs, laboratory test results, medication history, and surgical records. The investigators provide information on whether AKI develops within 48 hours and the top 10 explanatory factors for predicting AKI to the physician.
Study: NCT05605535

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Oregovomab
Description: 2 mg, dissolved in 2 mL of 0.9% Sodium Chloride Injection USP, then added to 50 mL of Sodium Chloride Injection USP infused over 20 ± 5 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 175 mg/m\^2, every 3 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel
Description: 175 mg/m\^2, every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC 5 or 6 IV Day 1 x 6 cycles (every 21 days)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carboplatin
Description: AUC 5 or 6 IV Day 1 x 6 cycles (every 21 days)

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 mg, dissolved in 2 mL of 0.9% Sodium Chloride Injection USP, then added to 50 mL of Sodium Chloride Injection USP infused over 20 ± 5 minutes
Study: NCT05723250

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Table-based Educational Intervention
Description: Tablet based educational tool with videos about care coordination, cancer knowledge and self-advocacy.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Table-based Educational Intervention
Description: Tablet based educational tool with videos about care coordination, cancer knowledge and self-advocacy.
Study: NCT04674072

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reverse Nordic curl exercise
Description: The reverse Nordic curl is a body-weight exercise which mainly works the quadriceps and hip flexors. It has a large eccentric component, meaning the muscles are working whilst lengthening.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual warm up
Description: Usual warm up is defined as any basic exercises performed before a performance or practice to prepare the muscles for vigorous actions.
Study: NCT06005610

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol
Description: Oral 17-β estradiol 2 mg once daily will be initiated at study entry. At weeks 4, 12, 24, and 36, study clinicians may titrate 17-β estradiol in 2 mg increments to achieve the desired participant goals and target hormone concentrations, as measured locally at each visit.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol
Description: Oral 17-β estradiol 2 mg once daily will be initiated at study entry. At weeks 4, 12, 24, and 36, study clinicians may titrate 17-β estradiol in 2 mg increments to achieve the desired participant goals and target hormone concentrations, as measured locally at each visit.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol
Description: Oral 17-β estradiol 2 mg once daily will be initiated at study entry. At weeks 4, 12, 24, and 36, study clinicians may titrate 17-β estradiol in 2 mg increments to achieve the desired participant goals and target hormone concentrations, as measured locally at each visit.
Study: NCT05909358

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAd3
Description: CAd3 candidate vaccine which is one of the investigational products

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAdox1
Description: ChAdox1 candidate vaccine which is one of the investigational products

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rVSV-SUDV
Description: rVSV-SUDV candidate vaccine which is one of the investigational products

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Placebo
Study: NCT04964973

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Post-surgical physiotherapeutic activity.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental
Description: Post-surgical physiotherapeutic activity with the application of the technique

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Post-surgical physiotherapeutic activity with the application of the non-activated technique